Réka Csáki, Chandran Nagaraj, János Almássy, Mohammad Ali Khozeimeh, Dusan Jeremic, Horst Olschewski, Alice Dobolyi, Konrad Hoetzenecker, Andrea Olschewski, Péter Enyedi, Miklós Lengyel
{"title":"The TREK-1 potassium channel is a potential pharmacological target for vasorelaxation in pulmonary hypertension","authors":"Réka Csáki, Chandran Nagaraj, János Almássy, Mohammad Ali Khozeimeh, Dusan Jeremic, Horst Olschewski, Alice Dobolyi, Konrad Hoetzenecker, Andrea Olschewski, Péter Enyedi, Miklós Lengyel","doi":"10.1111/bph.16426","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and purpose</h3>\n \n <p>Pulmonary arterial hypertension (PAH) is a progressive disease in which chronic membrane potential (E<sub>m</sub>) depolarisation of the pulmonary arterial smooth muscle cells (PASMCs) causes calcium overload, a key pathological alteration. Under resting conditions, the negative E<sub>m</sub> is mainly set by two pore domain potassium (K<sub>2P</sub>) channels, of which the TASK-1 has been extensively investigated.</p>\n </section>\n \n <section>\n \n <h3> Experimental Approach</h3>\n \n <p>Ion channel currents and membrane potential of primary cultured human(h) PASMCs were measured using the voltage- and current clamp methods. Intracellular [Ca<sup>2+</sup>] was monitored using fluorescent microscopy. Pulmonary BP and vascular tone measurements were also performed <i>ex vivo</i> using a rat PAH model.</p>\n </section>\n \n <section>\n \n <h3> Key Results</h3>\n \n <p>TREK-1 was the most abundantly expressed K<sub>2P</sub> in hPASMCs of healthy donors and idiopathic(I) PAH patients. Background K<sup>+</sup>-current was similar in hPASMCs for both groups and significantly enhanced by the TREK activator ML-335. In donor hPASMCs, siRNA silencing or pharmacological inhibition of TREK-1 caused depolarisation, reminiscent of the electrophysiological phenotype of idiopathic PAH. ML-335 hyperpolarised donor hPASMCs and normalised the E<sub>m</sub> of IPAH hPASMCs. A close link was found between TREK-1 activity and intracellular Ca<sup>2+</sup>-signalling using a channel activator, ML-335, and an inhibitor, spadin. In the rat, ML-335 relaxed isolated pre-constricted pulmonary arteries and significantly decreased pulmonary arterial pressure in the isolated perfused lung.</p>\n </section>\n \n <section>\n \n <h3> Conclusions and Implications</h3>\n \n <p>These data suggest that TREK-1is a key factor in E<sub>m</sub> setting and Ca<sup>2+</sup> homeostasis of hPASMC, and therefore, essential for maintenance of a low resting pulmonary vascular tone. Thus TREK-1 may represent a new therapeutic target for PAH.</p>\n </section>\n </div>","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":null,"pages":null},"PeriodicalIF":6.8000,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bph.16426","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bph.16426","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and purpose
Pulmonary arterial hypertension (PAH) is a progressive disease in which chronic membrane potential (Em) depolarisation of the pulmonary arterial smooth muscle cells (PASMCs) causes calcium overload, a key pathological alteration. Under resting conditions, the negative Em is mainly set by two pore domain potassium (K2P) channels, of which the TASK-1 has been extensively investigated.
Experimental Approach
Ion channel currents and membrane potential of primary cultured human(h) PASMCs were measured using the voltage- and current clamp methods. Intracellular [Ca2+] was monitored using fluorescent microscopy. Pulmonary BP and vascular tone measurements were also performed ex vivo using a rat PAH model.
Key Results
TREK-1 was the most abundantly expressed K2P in hPASMCs of healthy donors and idiopathic(I) PAH patients. Background K+-current was similar in hPASMCs for both groups and significantly enhanced by the TREK activator ML-335. In donor hPASMCs, siRNA silencing or pharmacological inhibition of TREK-1 caused depolarisation, reminiscent of the electrophysiological phenotype of idiopathic PAH. ML-335 hyperpolarised donor hPASMCs and normalised the Em of IPAH hPASMCs. A close link was found between TREK-1 activity and intracellular Ca2+-signalling using a channel activator, ML-335, and an inhibitor, spadin. In the rat, ML-335 relaxed isolated pre-constricted pulmonary arteries and significantly decreased pulmonary arterial pressure in the isolated perfused lung.
Conclusions and Implications
These data suggest that TREK-1is a key factor in Em setting and Ca2+ homeostasis of hPASMC, and therefore, essential for maintenance of a low resting pulmonary vascular tone. Thus TREK-1 may represent a new therapeutic target for PAH.
期刊介绍:
The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries.
Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues.
In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.